In an effort to combat cardiovascular disease and address its primary risk factors, Novartis, the global drugmaker, has launched an ambitious initiative in collaboration with key partners in the United Kingdom. The Novartis Biome UK Heart Health Catalyst 2022 is set to fund early-stage firms and researchers, focusing on innovative digital solutions and noninvasive approaches to manage blood pressure and track cholesterol levels.
This transformative partnership brings together Novartis’ London-based Biome UK incubator, renowned medical technology company Medtronic, RYSE Asset Management, Chelsea and Westminster Hospital NHS Foundation Trust, and CW+.
The catalyst program comes at a critical time, as the COVID-19 pandemic has necessitated rapid advancements in digital health programs. By leveraging state-of-the-art technologies and new care models, Novartis aims to bridge healthcare disparities and bring about tangible improvements in the UK’s health system. Marie-Andrée Gamache, head of Novartis Innovative Medicines in the UK and Ireland, expressed confidence in the partnership’s potential to drive real change for the estimated 7 million people in the UK living with cardiovascular disease.
Under the Catalyst program, promising applicants will have the opportunity to secure funding to develop groundbreaking solutions. Novartis Biome UK will focus on medication development, while Medtronic will lend its expertise in medtech, aligning their efforts to tackle cardiovascular disease comprehensively. RYSE Asset Management’s significant investment of up to £3 million in the initiatives will provide crucial support to foster innovation and advancements in this vital field.
The Chelsea and Westminster Hospital NHS Foundation Trust’s CW Innovation program is one of the partnership’s key components. This program will establish a real-world data initiative to evaluate the effectiveness of developers’ solutions in NHS clinics, ensuring that the innovations are robust and practical for real-world implementation.
The Catalyst program is open to applicants until August, after which a panel of experts will evaluate the proposals and select finalists. In late September, the chosen finalists will present their ideas to a live audience at the Healthcare Excellence Through Technology conference in London. The conference will serve as a platform for innovators to showcase their work, and the winners will be announced at this event.
This initiative aligns with Novartis’ commitment to pioneering healthcare advancements and promoting a healthier world. By investing in early-stage firms and researchers, the program seeks to catalyze transformative breakthroughs in blood pressure management and cholesterol tracking. With Medtronic’s support in the field of medtech and RYSE Asset Management’s substantial financial backing, the program is poised to make a significant impact on cardiovascular healthcare.
Moreover, the collaboration’s focus on digital health solutions is timely as the world moves towards a more connected and technology-driven era. The potential benefits of integrating innovative technologies into healthcare systems are vast, ranging from enhanced patient care and streamlined treatments to more efficient data management and improved health outcomes.
As the Catalyst program gains momentum, it is expected to attract top-tier talent and foster a culture of innovation within the UK’s healthcare ecosystem. By combining the strengths of pharmaceuticals, medtech, and finance, this dynamic partnership will drive substantial progress in cardiovascular healthcare and pave the way for a healthier, heart-conscious future for millions of people in the UK and beyond.